Medical device sunscreen for skin with actinic keratosis and increased risk of non-melanoma skin cancer.
Eryfotona® AK-NMSC is a medical device sunscreen with SPF 100+, specifically designed for the prevention, management, and adjunctive treatment of actinic keratosis (AK) and non-melanoma skin cancer (NMSC). It provides daily photoprotection for the face, scalp, and other photo-exposed areas, while also contributing to the improvement of the subclinical field of cancerization.
Its advanced formulation reflects modern dermato-genetic science and is based on the patented DNA Repairsomes® technology, which contains photolyase, a DNA repair enzyme that acts in the restoration of UVB-induced mutations. In combination with selected broad-spectrum chemical and physical filters, and ingredients such as Bisabolol, Vitamin E, and Panthenol, Eryfotona AK-NMSC effectively protects, soothes, and hydrates the skin, supporting the natural repair mechanisms & cellular homeostasis of the epidermis. Its lightweight, non-greasy texture is rapidly absorbed and suitable for daily and long-term use.
- Contributes to a significant reduction in the number of actinic keratosis lesions, with up to -75% after 3 months of continuous use.
- Reduces the appearance of new AK lesions, with 86% of patients remaining free of new lesions after 6 months of use.
- Contributes to the restoration of epidermal cellular homeostasis, with reduced overexpression of CPI-17, which is associated with carcinogenesis.
- Supports healing and reduces recurrences when used adjunctively after photodynamic therapy, cryotherapy, or laser treatment, with demonstrated good tolerability.
- Reduces the mean number of new AK lesions, with 1 new lesion versus 2.7 compared to the use of standard sunscreen protection (SPF 50+).
- Improves the subclinical field of cancerization, with reduced expression of carcinogenesis markers such as TP53, P21, and PCNA.
- Provides very high and stable photoprotection (SPF 100+), essential for high-risk patients and individuals with a history of intense photoaging.
- Suitable for long-term daily use, with good tolerability and no greasy residue.
- Dermatologically tested and fully supported by published scientific literature.
How to use:Shake before use. Apply generously to the entire affected area and other areas at risk from chronic sun exposure, such as the face, forehead, ears, décolletage, bald spots, and backs of the hands. Do this twice a day: in the morning and at midday. Use daily. The photolyase is activated by visible light. In case of direct sun exposure, reapply the product every two hours. Apply only to clean, unbroken skin. Daily and continuous use is essential for the prevention and adjunctive treatment of AK and NMSC. In patients undergoing pharmacological treatment or surgery for AK or NMSC, begin treatment with Eryfotona® AK-NMSC once the lesions have closed.
Precautions:Actinic keratosis and other forms of non-melanoma skin cancer are diseases caused by chronic sun exposure. If you have had AK or NMSC, you should avoid direct sun exposure. It is not recommended for use in children, pregnant women, or while breastfeeding. Avoid contact with the eyes and mucous membranes. In case of a possible adverse reaction to any of the ingredients, discontinue treatment and consult a doctor. Keep out of reach of children.
ISDIN, S.A
Provençals 33 Barcelona 08019 (Spain)
www.isdin.com
Barcode: 8470001658531
